MedTrace Logo

Impact of Primary Language on Treatment and Outcomes in Inflammatory Bowel Disease

NCT06405503 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 206

Last updated 2024-05-08

No results posted yet for this study

Summary

A thorough discussion of treatment options to manage inflammatory bowel disease (IBD), including the risks and benefits of each class of medication, can be a complex discussion and time consuming. Having to use a translator adds an additional layer of time and complexity to these discussions as well as potential misunderstanding. Further, in addition to language, cultural differences can also play into treatment acceptance.

This study aims to determine the impact of primary language on the selection of treatment for IBD and on disease outcomes.

Conditions

Interventions

OTHER

NO INTERVENTION

NO INTERVENTION - OBSERVATIONAL ONLY

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Yale University

    collaborator OTHER

  • University of Texas at Austin

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06405503 on ClinicalTrials.gov